The American College of Radiology® (ACR®) developed a detailed summary of the 2025 Medicare Physician Fee Schedule (MPFS) proposed rule released by the Centers for Medicare and Medicaid Services (CMS) July 10. The summary outlines Medicare payment provisions and updates to the Quality Payment Program. If finalized, the rule changes for most of the provisions would take effect Jan. 1, 2025. The ACR plans to submit comments to CMS by its Sept. 9 deadline.
CMS estimates an overall impact of the MPFS proposed changes to radiology, nuclear medicine and radiation oncology to be a neutral 0%, while interventional radiology would see an aggregate decrease of 2% if the provisions within the proposed rule are finalized. However, this does not take into account the impact of the expiration of the conversion factor payment increase provided by the Consolidated Appropriations Act, 2024. CMS estimates a CY 2025 conversion factor of $32.3562 compared to the 2024 conversion factor of $33.2875. The proposed 2025 conversion factor is approximately 2.8% lower than the current 2024 conversion factor.
Send questions about payment provisions to EconAdmin@acr.org, or nrdrsupport@acr.org for questions about the Quality Payment Program.
Make America Healthy Again
President Trump released an Executive Order (EO) establishing the "Make America Healthy Again (MAHA) Commission,” Feb. 13 to be led by the new Department of Health and Human Services Secretary Robert F. Kennedy Jr.
Read moreScope of Practice Bills Introduced At State Legislative Level
The American College of Radiology® (ACR®) is tracking more than 58 scope of practice bills across 22 states with more expected to be considered.
Read moreACR Others Challenge MAC Position on Minimally Invasive Arthrodesis of the Sacroiliac Joint
The American College of Radiology® (ACR®) and other medical specialty societies that use or perform interventional pain and spine procedures told three of the seven Medicare Administrative Contractors (MACs) that implementation of a new policy as written could limit access to a safe, effective and durable treatment option, potentially exacerbating healthcare disparities among Medicare patients.
Read more